Case report of immunoglobulin therapy for aggressive, atypical MOG-antibody-associated disease

Lire cet article en français


  • Identification of anti-myelin oligodendrocyte glycoprotein-antibody-associated disease (MOG-Ab AD) in a patient with an aggressive and atypical disease course led to successful treatment with intravenous immunoglobulin (IVIg), supporting replication of the treatment in a larger case series.

Why this matters

  • As it emerges as a disease state distinct from multiple sclerosis (MS), the course of MOG-Ab AD, therapeutic options, and treatment durations remain unclear, and case reports of successful management can guide future investigations.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.